Genetically modified T cells fight haematological cancer

Pivotal ruxolitinib data shows promise for patients with PV

Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL

Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise patient safety?

ASCO 2014 roundup

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Emerging pathways in immunotherapy

Myeloma genomics and Immuno-oncology

Novel targets and immune based therapy in myeloma